Market Overview:
The global uterine fibroid embolization agents market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of uterine fibroids, technological advancements in embolization agents, and rising demand for minimally invasive procedures. Based on type, the global uterine fibroid embolization agents market is segmented into gelatin sponge, polyvinyl alcohol (PVA) particles, trisacryl gelatin microspheres (TAGM), polymethyl methacrylate (PMMA) microspheres, and others. The PVA particles segment is expected to account for the largest share of the global uterine fibroid embolization agents market in 2018. This can be attributed to its high biocompatibility and low immunogenicity. Based on application, the global uterine fibroid embolization agents market is segmented into clinical research institutes, hospitals & surgical centers, and others.
Product Definition:
Uterine fibroid embolization agents are used to treat uterine fibroids. These agents help to block the blood supply to the fibroids, which causes them to shrink. Uterine fibroid embolization is a minimally invasive procedure that can be used to treat uterine fibroids that are causing symptoms such as pain, heavy bleeding, and infertility.
Gelatin Sponge:
Gelatin is a protein derived from collagen. It is widely used in pharmaceutical and cosmetic industries as an excipient or filler for tablets, capsules, syrups, solutions and suspensions among others. The demand for gelatin sponges in uterine fibroid embolization (UFEM) agents market is expected to grow on account of the increasing prevalence of uterine fibroids globally coupled with rising awareness about the use of this product as a drug carrier.
Polyvinyl Alcohol (PVA) Particles:
Polyvinyl alcohol (PVA) particles are small, biodegradable polymer particles that consist of a hydrophilic core covered with an outer layer of hydrophobic polymers. PVA is used as a drug carrier in the treatment of cancer and other diseases. Polyvinyl alcohol has been approved by the U.
Application Insights:
Based on application, the global uterine fibroid embolization agents market is segmented into clinical research institutes, hospital, surgical centers and others. The other applications include diagnostic laboratories and academic institutions. The segment with the highest market share in 2017 was dominated by hospital-based settings owing to a high prevalence of chronic diseases such as cancer and cardiovascular diseases that require treatment at hospitals or medical centers.
The clinical research institutes held a significant share of the overall revenue in 2017 due to an increase in government funding for various types of clinical trials across the globe. In addition, an increase in R&D investments by companies for developing new products is expected to boost growth over the forecast period.
Regional Analysis:
North America dominated the global uterine fibroids embolization agents market in 2017. This is due to the presence of well-established healthcare infrastructure, high adoption rate of advanced technologies, and availability of skilled urologists & gynecologists in this region. Moreover, increasing incidence rates of UF are also contributing towards regional growth. For instance, according to data published by National Cancer Institute (NCI), around 5% women are estimated to be diagnosed with invasive UF during their lifetime and approximately 1 million new cases were reported in United States (US) alone in 2015.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as rising awareness about fibroids treatment options among patients coupled with growing medical tourism industry especially after launch of affordable health plans by private insurance companies like Aetna Inc., Humana Inc.
Growth Factors:
- Increasing incidence of uterine fibroids
- Growing awareness about the benefits of uterine fibroid embolization agents
- Rising demand for minimally invasive procedures for the treatment of uterine fibroids
- Technological advancements in uterine fibroid embolization agents market
- Growing number of women opting for surgical treatment for uterine fibroids
Scope Of The Report
Report Attributes
Report Details
Report Title
Uterine Fibroid Embolization Agents Market Research Report
By Type
Gelatin Sponge, Polyvinyl Alcohol (PVA) Particles, Trisacryl Gelatin Microspheres (TAGM), Polymethyl Methacrylate (PMMA) Microspheres, Others
By Application
Clinical Research Institutes, Hospital, Surgical Centers, Others
By Companies
Astellas Pharma, Nippon Kayaku, Pfizer, Boston Scientific Corporation, Merit Medical Systems, Cook Medical, Astellas Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
170
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Uterine Fibroid Embolization Agents Market Report Segments:
The global Uterine Fibroid Embolization Agents market is segmented on the basis of:
Types
Gelatin Sponge, Polyvinyl Alcohol (PVA) Particles, Trisacryl Gelatin Microspheres (TAGM), Polymethyl Methacrylate (PMMA) Microspheres, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinical Research Institutes, Hospital, Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- Nippon Kayaku
- Pfizer
- Boston Scientific Corporation
- Merit Medical Systems
- Cook Medical
- Astellas Pharma
Highlights of The Uterine Fibroid Embolization Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gelatin Sponge
- Polyvinyl Alcohol (PVA) Particles
- Trisacryl Gelatin Microspheres (TAGM)
- Polymethyl Methacrylate (PMMA) Microspheres
- Others
- By Application:
- Clinical Research Institutes
- Hospital
- Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Uterine Fibroid Embolization Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Uterine fibroid embolization agents are medications that are used to block the flow of blood from the uterus. This can help to reduce the size and number of uterine fibroids.
Some of the key players operating in the uterine fibroid embolization agents market are Astellas Pharma, Nippon Kayaku, Pfizer, Boston Scientific Corporation, Merit Medical Systems, Cook Medical, Astellas Pharma.
The uterine fibroid embolization agents market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Uterine Fibroid Embolization Agents Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Uterine Fibroid Embolization Agents Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Uterine Fibroid Embolization Agents Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Uterine Fibroid Embolization Agents Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Uterine Fibroid Embolization Agents Market Size & Forecast, 2018-2028 4.5.1 Uterine Fibroid Embolization Agents Market Size and Y-o-Y Growth 4.5.2 Uterine Fibroid Embolization Agents Market Absolute $ Opportunity
Chapter 5 Global Uterine Fibroid Embolization Agents Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Uterine Fibroid Embolization Agents Market Size Forecast by Type
5.2.1 Gelatin Sponge
5.2.2 Polyvinyl Alcohol (PVA) Particles
5.2.3 Trisacryl Gelatin Microspheres (TAGM)
5.2.4 Polymethyl Methacrylate (PMMA) Microspheres
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Uterine Fibroid Embolization Agents Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Uterine Fibroid Embolization Agents Market Size Forecast by Applications
6.2.1 Clinical Research Institutes
6.2.2 Hospital
6.2.3 Surgical Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Uterine Fibroid Embolization Agents Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Uterine Fibroid Embolization Agents Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Uterine Fibroid Embolization Agents Analysis and Forecast
9.1 Introduction
9.2 North America Uterine Fibroid Embolization Agents Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Uterine Fibroid Embolization Agents Market Size Forecast by Type
9.6.1 Gelatin Sponge
9.6.2 Polyvinyl Alcohol (PVA) Particles
9.6.3 Trisacryl Gelatin Microspheres (TAGM)
9.6.4 Polymethyl Methacrylate (PMMA) Microspheres
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Uterine Fibroid Embolization Agents Market Size Forecast by Applications
9.10.1 Clinical Research Institutes
9.10.2 Hospital
9.10.3 Surgical Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Uterine Fibroid Embolization Agents Analysis and Forecast
10.1 Introduction
10.2 Europe Uterine Fibroid Embolization Agents Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Uterine Fibroid Embolization Agents Market Size Forecast by Type
10.6.1 Gelatin Sponge
10.6.2 Polyvinyl Alcohol (PVA) Particles
10.6.3 Trisacryl Gelatin Microspheres (TAGM)
10.6.4 Polymethyl Methacrylate (PMMA) Microspheres
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Uterine Fibroid Embolization Agents Market Size Forecast by Applications
10.10.1 Clinical Research Institutes
10.10.2 Hospital
10.10.3 Surgical Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Uterine Fibroid Embolization Agents Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Uterine Fibroid Embolization Agents Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Uterine Fibroid Embolization Agents Market Size Forecast by Type
11.6.1 Gelatin Sponge
11.6.2 Polyvinyl Alcohol (PVA) Particles
11.6.3 Trisacryl Gelatin Microspheres (TAGM)
11.6.4 Polymethyl Methacrylate (PMMA) Microspheres
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Uterine Fibroid Embolization Agents Market Size Forecast by Applications
11.10.1 Clinical Research Institutes
11.10.2 Hospital
11.10.3 Surgical Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Uterine Fibroid Embolization Agents Analysis and Forecast
12.1 Introduction
12.2 Latin America Uterine Fibroid Embolization Agents Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Uterine Fibroid Embolization Agents Market Size Forecast by Type
12.6.1 Gelatin Sponge
12.6.2 Polyvinyl Alcohol (PVA) Particles
12.6.3 Trisacryl Gelatin Microspheres (TAGM)
12.6.4 Polymethyl Methacrylate (PMMA) Microspheres
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Uterine Fibroid Embolization Agents Market Size Forecast by Applications
12.10.1 Clinical Research Institutes
12.10.2 Hospital
12.10.3 Surgical Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Uterine Fibroid Embolization Agents Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Uterine Fibroid Embolization Agents Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Uterine Fibroid Embolization Agents Market Size Forecast by Type
13.6.1 Gelatin Sponge
13.6.2 Polyvinyl Alcohol (PVA) Particles
13.6.3 Trisacryl Gelatin Microspheres (TAGM)
13.6.4 Polymethyl Methacrylate (PMMA) Microspheres
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Uterine Fibroid Embolization Agents Market Size Forecast by Applications
13.10.1 Clinical Research Institutes
13.10.2 Hospital
13.10.3 Surgical Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Uterine Fibroid Embolization Agents Market: Competitive Dashboard
14.2 Global Uterine Fibroid Embolization Agents Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma
14.3.2 Nippon Kayaku
14.3.3 Pfizer
14.3.4 Boston Scientific Corporation
14.3.5 Merit Medical Systems
14.3.6 Cook Medical
14.3.7 Astellas Pharma